AAT Augmentation denied as not FDA-approved for this use by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for aat augmentation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS May Issue a "Not FDA-Approved" Denial for AAT Augmentation

This denial reason is surprising because multiple AAT augmentation products hold FDA approval specifically for the condition they treat. A "not FDA-approved" denial typically arises from one of three administrative errors: (1) an incorrect drug code was submitted on the claim, (2) the claim was reviewed against the wrong coverage policy, or (3) the plan's system failed to recognize the product's approved indication. In rare cases, a plan may argue that the specific use as prescribed (for example, a dosing schedule or patient population not described in the label) falls outside the FDA-approved indication.

## Why This Is Appealable

Because FDA approval for AAT augmentation in hereditary AAT deficiency is a matter of public record, a denial on this basis is among the most straightforwardly reversible. You do not need to argue clinical judgment — you need to establish the regulatory fact. Under ACA §2719 and ERISA §503, you are entitled to a full-and-fair internal review and, if that fails, independent external review (request within 4 months of final internal denial).

## Documentation to Gather

• FDA prescribing information: Download the current FDA-approved prescribing label for the specific product prescribed. The "Indications and Usage" section will confirm the approved indication. Attach this to your appeal as Exhibit A.
• Prescriber attestation: A letter from your physician confirming that the drug was prescribed for its FDA-approved indication, in the manner described in the label.
• Claim documentation: The original claim submission showing the correct drug name, NDC code, and diagnosis code (ICD-10 for AAT deficiency), so the reviewer can confirm there was no coding error.
• Denial letter analysis: Identify in the denial letter exactly what basis BCBS used — if they cite a specific policy number or claim a use is "off-label," address that directly.

## Criteria-Mapping Structure

Create a table with three columns: (1) the basis BCBS cited for the "not FDA-approved" finding, (2) the relevant section of the FDA prescribing label that contradicts it, and (3) the clinical record confirming the on-label use. This makes the factual error impossible to overlook.

## Timeline

1. File internal appeal within 180 days of denial. 2. BCBS must decide within 30 days (pre-service) or 60 days (post-service). 3. If internal appeal is denied, request external review within 4 months — a regulatory-fact error is exactly the kind of issue independent reviewers resolve quickly.